Renaissance Technologies LLC grew its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 7.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,926,150 shares of the company's stock after purchasing an additional 139,722 shares during the quarter. Renaissance Technologies LLC owned approximately 0.29% of Genmab A/S worth $40,199,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brandywine Global Investment Management LLC bought a new stake in shares of Genmab A/S during the fourth quarter valued at about $33,804,000. Russell Investments Group Ltd. increased its position in Genmab A/S by 18,959.1% during the fourth quarter. Russell Investments Group Ltd. now owns 510,784 shares of the company's stock worth $10,660,000 after acquiring an additional 508,104 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Genmab A/S by 3,049.3% in the 4th quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company's stock valued at $8,507,000 after buying an additional 394,670 shares in the last quarter. Trexquant Investment LP grew its stake in shares of Genmab A/S by 495.1% in the 4th quarter. Trexquant Investment LP now owns 379,936 shares of the company's stock valued at $7,929,000 after purchasing an additional 316,089 shares during the period. Finally, ABC Arbitrage SA acquired a new position in Genmab A/S during the fourth quarter worth $3,692,000. Institutional investors and hedge funds own 7.07% of the company's stock.
Analyst Ratings Changes
Several research firms have recently commented on GMAB. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target for the company in a research report on Thursday, February 13th. Truist Financial reduced their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Finally, HC Wainwright reiterated a "buy" rating and set a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $39.17.
Get Our Latest Stock Analysis on GMAB
Genmab A/S Trading Up 0.7 %
Shares of GMAB stock traded up $0.13 during mid-day trading on Wednesday, reaching $19.64. The stock had a trading volume of 342,894 shares, compared to its average volume of 1,024,347. The business's fifty day moving average is $20.48 and its 200-day moving average is $21.24. The firm has a market cap of $13.00 billion, a price-to-earnings ratio of 11.29, a PEG ratio of 2.65 and a beta of 1.07. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $30.41.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, analysts forecast that Genmab A/S will post 1.45 earnings per share for the current year.
Genmab A/S Company Profile
(
Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
